Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2004-08-02
2010-11-23
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C540S484000
Reexamination Certificate
active
07838029
ABSTRACT:
A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.
REFERENCES:
patent: 4062848 (1977-12-01), van der Burg
patent: 5082864 (1992-01-01), Van den Oetelaar et al.
patent: 5112616 (1992-05-01), McCarty
patent: 5178878 (1993-01-01), Wehling et al.
patent: 5208261 (1993-05-01), Van Den Oetelaar et al.
patent: 5238688 (1993-08-01), Beuving et al.
patent: 5464632 (1995-11-01), Cousin et al.
patent: 5725884 (1998-03-01), Sherwood et al.
patent: 5837292 (1998-11-01), Dijkgraaf et al.
patent: 5955107 (1999-09-01), Augello et al.
patent: 5958453 (1999-09-01), Ohno et al.
patent: 5977099 (1999-11-01), Nickolson
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6040301 (2000-03-01), Skrabanja et al.
patent: 6114324 (2000-09-01), Skrabanja et al.
patent: 6150353 (2000-11-01), Broekkamp et al.
patent: 6211171 (2001-04-01), Sawynok et al.
patent: 6228875 (2001-05-01), Tsai et al.
patent: 6281207 (2001-08-01), Richter et al.
patent: 6294198 (2001-09-01), Vilkov
patent: 6303595 (2001-10-01), Andrews
patent: 6328994 (2001-12-01), Shimizu et al.
patent: 6376668 (2002-04-01), Iishi et al.
patent: 6399310 (2002-06-01), Murphy, Jr. et al.
patent: 6437120 (2002-08-01), Iishi et al.
patent: 6448293 (2002-09-01), Andrews et al.
patent: 6482440 (2002-11-01), Zemlan et al.
patent: 6495685 (2002-12-01), Maeda et al.
patent: 6545149 (2003-04-01), Singer et al.
patent: 6552014 (2003-04-01), Serebruany et al.
patent: 6552189 (2003-04-01), Iishi et al.
patent: 6576764 (2003-06-01), Singer et al.
patent: 6589556 (2003-07-01), Cherukuri
patent: 6610747 (2003-08-01), Adam et al.
patent: 6630504 (2003-10-01), Andrews et al.
patent: 6649605 (2003-11-01), Olesen et al.
patent: 6660730 (2003-12-01), Maeda et al.
patent: 6723348 (2004-04-01), Faham et al.
patent: 6723845 (2004-04-01), Iishi et al.
patent: 6774230 (2004-08-01), Metzger et al.
patent: 2001/0009678 (2001-07-01), Toshihiro et al.
patent: 2001/0010825 (2001-08-01), Shimizu et al.
patent: 2002/0049233 (2002-04-01), Kararli et al.
patent: 2002/0052395 (2002-05-01), Andrews et al.
patent: 2002/0071864 (2002-06-01), Kim et al.
patent: 2002/0091129 (2002-07-01), Boolell
patent: 2002/0142034 (2002-10-01), Shimizu et al.
patent: 2002/0183303 (2002-12-01), Andrews et al.
patent: 2003/0017202 (2003-01-01), Bunick et al.
patent: 2003/0026835 (2003-02-01), Nishii et al.
patent: 2003/0035833 (2003-02-01), He
patent: 2003/0054037 (2003-03-01), Babcock et al.
patent: 2003/0054038 (2003-03-01), Crew et al.
patent: 2003/0060456 (2003-03-01), Adam et al.
patent: 2003/0072801 (2003-04-01), Curatolo et al.
patent: 2003/0099700 (2003-05-01), Faham et al.
patent: 2003/0104063 (2003-06-01), Babcock et al.
patent: 2003/0165566 (2003-09-01), O'Toole et al.
patent: 2003/0170309 (2003-09-01), Babcock et al.
patent: 2003/0224043 (2003-12-01), Appel et al.
patent: 2003/0228358 (2003-12-01), Perlman et al.
patent: 2003/0229027 (2003-12-01), Eissens et al.
patent: 2004/0028729 (2004-02-01), Shojaei et al.
patent: 2004/0033258 (2004-02-01), Koike
patent: 2004/0058896 (2004-03-01), Dietrich et al.
patent: 2004/0097509 (2004-05-01), Andrews et al.
patent: 2004/0122106 (2004-06-01), Ohta et al.
patent: 2004/0138263 (2004-07-01), D'Angio et al.
patent: 2004/0142034 (2004-07-01), Thor et al.
patent: 2005/0013857 (2005-01-01), Fu et al.
patent: 2005/0208141 (2005-09-01), Farber et al.
patent: 0 839 526 (1998-05-01), None
patent: 1161941 (2001-12-01), None
patent: 1203580 (2002-05-01), None
patent: WO 8705804 (1987-10-01), None
patent: WO 98/53798 (1998-12-01), None
patent: WO 9853798 (1998-12-01), None
patent: WO 0269933 (2002-09-01), None
patent: WO 03072084 (2003-09-01), None
Marc Gordon, “Process Considerations in Reducing Tablet Friability and Their Effect on in vitro Dissolution”, Jan. 1994, Drug Development and industrial Pharmacy, vol. 20, issue 1, abstract.
Co-pending U.S. Appl. No. 10/923,021, inventors Ahmed, S., et al., filed Aug. 23, 2004 (Not Published).
Co-pending U.S. Appl. No. 11/048,120, inventors Ahmed, S., et al., filed Feb. 2, 2005 (Not Published).
Bi, Y.X., et al., “Evaluation of rapidly disintegrating tablets prepared by a direct compression method,”Drug Dev. Ind. Pharm.25:571-581, Marcel Dekker, Inc. (1999).
Bi, Y.X., et al., “Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral Cavity,”Chem. Pharm. Bull.44:2121-2127, Pharmaceutical Society of Japan (1996).
Davidson, N., et al., “Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: A multi-center, double-masked study,”Clin. Ther.21:492-502, Elsevier Science, Inc. (1999).
El-Arini, S.K. and Clas, S.D., “Evaluation of disintegration testing of different fast dissolving tablets using the texture analyzer,”Pharm. Dev. Technol.7:361-371, Marcel Dekker, Inc. (Aug. 2002).
Gan, T.J., et al., “Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery,”Anesth. Analg.94:1199-1200, International Anesthesia Research Society (Nov. 2002).
Habib, W., et al., “Fast-dissolve drug delivery systems,”Critical Reviews™ in Therapeutic Drug Carrier Systems 17:61-72, Begell House, Inc. (2000).
Hom, F.S. and Miskel, J.J., “Enhanced dissolution rates for a series of drugs as a function of dosage form design,”Intl. J. Law Sci.8:18-26, International Academy of Law and Science (1971).
Ishikawa, T., et al., “Preparation of rapidly disintegrating tablet using new types of microcrystalline cellulose (PH-M Series) and low substituted-hydroxypropylcellulose or spherical sugar granules by direct compression method,”Chem. Pharm. Bull. 49:134-139, Pharmaceutical Society of Japan (2001).
Koizumi, K., et al., “New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material,”Intl. J. Pharm.152:127-131, Elsevier Science B.V. (1997).
LeBourgeois, J.P., et al., “Efficacy of an ondansetron orally disintegrating tablet: A novel oral formulation of this 5-HT3receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis,”Clin. Oncol.11:340-347, The Royal College of Radiologists (1999).
Lehoczky, O., et al., “Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran™ Zydis™ for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients,”Neoplasma49:126-128, Cancer Research Institute of the Slovak Academy of Sciences (2002).
Liang, A.C. and Chen, L.H., “Fast-dissolving intraoral drug delivery systems,”Expert Opinion on Therapeutic Patents 11:981-986, Ashley Publications Ltd. (2001).
Lowenthal, W., “Mechanism of action of tablet disintegrants,”Pharmaceutica Acta Helvetiae 48:589-609, Elsevier B.V. (1973).
Massimo, G., et al., “Disintegration propensity of tablets evaluated by means of disintegrating force kinetics,”Pharm. Dev. Technol.5:163-169, Marcel Dekker, Inc. (2000).
Nakagami, H. and Nada, M., “The use of micronized cellulose disintegrants as insoluble swellable matrices for sustained-release tablets,”Drug Design and Delivery 7:321-332, Harwood Academic Publishers GmbH (1991).
Sastry, S.V., et al., “Recent technological advances in oral drug delivery—a review,”Pharm. Sci. Technol. Today3:138-145, Elsevier Science (2000).
Watanabe. Y., et al., “New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrant,”Biol. Pharm. Bull.18:1308-1310, Pharmaceutical Society of Japan
Ahmed Salah U.
Chowdhury Tahseen A.
Gorukanti Sudhir R.
Naringrekar Gandha V.
Carter Kendra D
Florek & Endres PLLC
Padmanabhan Sreeni
Watson Laboratories, Inc.
LandOfFree
Mirtazapine solid dosage forms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mirtazapine solid dosage forms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mirtazapine solid dosage forms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242591